comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 18:21:02 - browse：14

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： A public scorecard can help hold safety

focus

WSS

Amid AI frenzy, a top HHS official's quest to create safeguards

Group opposing PBM reform sets lobbying record

Medicare to cover more brain scans for Alzheimer’s patients

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Ebola: Gilead Sciences antiviral shows promise as new treatment

President Biden's budget: Here's what you might have missed

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

How to save PrEP access — and even expand it

AI can’t replace a physician’s gut feeling

In Memoriam: Notable people who died in 2023

At Orexo, a ‘turning point’ for everything but digital health

In Memoriam: Notable people who died in 2023

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Medicare proposal to cover medical devices draws a mixed reaction

Listen: Wegovy in the brain & pivotal Alzheimer's data

Wildfire smoke exposes gaps in outdoor worker protections

Boston's new lab space is opening empty

Wikipedia

FDA approves RSV monoclonal antibody for infants, toddlers

John Green on his newest strategy for fighting tuberculosis

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Why hospitals are withdrawing from US News rankings

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

As AI in medicine takes off, can 'human in the loop' prevent harm?

entertainment

focus

Wikipedia

hotspot